Press Releases

Here is an up-to-date collection of any information given to the press. It’s a big collection, so try not to look at it all in one sitting.

Press Releases

 
Press Releases
Date Title and Summary View
Oct 27, 2005 NEW YORK, NY - October 27, 2005 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP) announced today that Richard Bagley, President and Chief Operating Officer, will present at the MASS Opportunities Partnering Forum on Thursday, November 3, 2005 at 11:20 a.m. EST at the Hilton Boston Logan Airport in Boston, MA. Mr. Bagley will provide an overview of th...
PDF
Oct 19, 2005 NEW YORK, NY - October 19, 2005 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP) announ ced today that Dr. Jonathan Lewis, Chief Executive Officer, will present at the C.E. Unterberg, Towbin Life Sciences Conference on Wednesday, October 26, 2005 a t 4:00 p.m. EST at The New York Palace Hotel in New York, NY. Dr. Lewis will pro vide an overview of th...
PDF
Oct 14, 2005 New York, NY - October 14, 2005 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP) announced today that Dr. Jonathan Lewis, Chief Executive Officer, will present at the BIO Investor Forum on Thursday, October 20, 2005 at 11:40 a.m. PST (2:40 p.m. EST) at the Palace Hotel in San Francisco, CA. Dr. Lewis will provide an overview of the Company and an upd...
PDF
Sep 26, 2005 New York, NY - September 26, 2005 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP) announced today its ticker symbol has changed from "ESWB" to "ZIOP". The symbol change, which is effective as of the opening of business today, is a result of the Company's previously announced merger with ZIOPHARM, Inc. In connection with the merger, the combined comp...
PDF
Sep 15, 2005 New York, NY and Englewood, CO - September 15, 2005 - ZIOPHARM, Inc. (private) and EasyWeb, Inc. (OTC Bulletin Board: ESWB.OB) today announced that they have completed the previously announced merger of the two companies. The Company's common stock trades on the OTC Bulletin Board under the symbol "ESWB.OB" until a new ticker symbol has been ...
PDF
Jun 6, 2005 CHARLESTOWN, MA June 6, 2005 - ZIOPHARM, Inc. announced today that it had completed its Series A Convertible Preferred Stock offering. Paramount BioCapital, Inc. served as the lead placement agent and gross proceeds were approximately $18.1 million. The net proceeds from the Offering will be used for research and development, licensing fees a...
PDF
May 25, 2005 CHARLESTOWN, MA May 25, 2005 - ZIOPHARM, Inc. announced today that it has initiated its second phase I study to assess safety and dosing of ZIO-101, the Company's proprietary small molecule organic arsenic. This trial is being conducted in up to 40 patients with diverse solid tumors and complements the recently initiated phase I study in pati...
PDF
May 19, 2005 CHARLESTOWN, MA May 19, 2005 - ZIOPHARM, Inc. announced dosing of the first patient in its phase I study of the safety and dosing of ZIO-101, the Company's proprietary small molecule organic arsenic. The study, in up to 40 patients with diverse blood and bone marrow cancers, started on schedule just nine months after the Company licensed ZIO-...
PDF
Apr 19, 2005 NEW HAVEN, CT April 19, 2005 - ZIOPHARM, Inc. announced today Dr. Lee Roy Morgan presented the preclinical pharmacology and toxicology data for ZIO-201 (L-IPM , or lysine-isophosphoramide mustard) at the American Association for Cancer Research (AACR) meeting in Anaheim, California. ZIO-201 is the Company's proprietary alkylating drug and the...
PDF
Apr 5, 2005 NEW HAVEN, CT April 5, 2005 - ZIOPHARM, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug Application (IND) for the clinical development of its proprietary organic arsenic compound, ZIO-101. The Company plans to initiate a dose-ranging Phase I trial of ZIO-101 in patients with hema...
PDF
Page: FirstPrevious ...
41
NextLast